We created a biotech division in January 2012 in Barcelona premises. This division was the result of a deal with the French biotech group IPSEN. Thanks to that agreement we took over the necessary equipment, know-how and personnel with a wide experience in the development of biotechnological products.

With the development of biotechnology, disease treatment has suffered major transformations both from the point of view of the therapeutic approaches and from the type of molecules involved. Latest-generation pharmaceuticals are moving from synthetic small molecules to large biomolecules. Some examples of this new generation of biopharmaceuticals are hormone peptides, recombinant proteins, monoclonal and therapeutic antibodies, antibody drug conjugates, fusion proteins, oligonucleotides, silent RNA, recombinant  vaccines, etc. Due to the special properties of biopharmaceuticals like their high molecular weight, high structural complexity and mode of action, the regulatory requirements for these molecules differ a lot from the requirements for small molecules. Indeed, a large list of tests are required to characterize the quality of the biopharmaceutical drug, which is known as the analytical fingerprint.

In addition pharmacokinetic studies require specific bioanalytical methods like immunological or innovative mass spectrometry methods. Whereas metabolism plays a very limited role in the biotransformation of these molecules, immunogenicity has turned into the major safety issue for them. Because of this, both FDA and EMA have published several guidelines to describe how to detect and study the development of spontaneous antibodies against the biopharmaceutical drug (ADA).


Chemistry, Manufacturing & Control analytical services are conducted under GMP compliance. During development phases may be executed under GLP if it is a Client's requirement.



The release of a biosimilar product into the market is extremely challanging. By one hand only a very well equiped laboratory may have the cappabilities to afford such activity, ensuring purity, identity, and potency. By the other hand GMP certificate and manufacturing authorization should be available at testing site, which is subject to periodic inspection of regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Working with biologic drugs represents a huge analytical effort to deeply understand the whole molecule characteristics. Different methods and technologies are needed to get the analytical fingerprint. An extensive analytical characterization based on an ortogonal approach is a key element for the project success. We can afford complex characterization projects of innovative biologics or biosimilars comparison.

The devices used for inhaled and nasal drug delivery are collectively referred to as Orally Inhaled and Nasal Drug Products (OINDPs). The range of products available is broad, encompassing inhalers (metereddose, dry powder and aqueous droplet), nebulisers (jet, ultrasonic and vibrating mesh) and nasal (aqueous based, dry powder and propellant based). Two of the main factors largely recognised as Critical Quality Attributes in the testing of OINDPs are delivered dose and particle size.

In recent years, the pharmaceutical industry has developed a better understanding of the impact of extractables and leachables on patient safety and drug product interaction, leading to increased scrutiny by the regulators. A study should be conducted to determine the extractables profile from the container closure components that are in contact with the formulation during storage and/or use.

We have a wide experience in performing analytical tests for APIsexcipientsintermediate productsfinished productspackaging materials and process environment samples. The most suitable method is used, according to customer specifications or the relevant Pharmacopoeias description (EP, USP, BP, JP). If non-compendial methods should be used, we perform the method development and validation from scratch or the method transfer from the manufacturer.

We have a comprehensive knowledge in the development and validation of analytical proprietary and non-proprietary methods for excipients, APIs, intermediate products and finished products, according to the ICH Q2 (R1) in line with Q6A and Q6B. Our methods are ready for transfer to contract-giver, in compliance with EU-GMP chapter 6, performing a comparative test, a co-validation in two sites or a revalidation.

We provide full service of ICH and on-going stability programs for third parties. The services, at client's choice, can include: method transfer, method improvement, analytical standards management, storage at different conditions, scheduling of analytical timepoints, full analysis and out-of-trend (OOT) and out-of-specification (OOS) management. These tasks are always performed according to procedures agreed with the client.

We provide microbiological testing for sterile and non-sterile APIs and drug products. A fully-equiped laboratory is available including a cleanroom with airlock tecnology and HEPA filters for the most sensitive operations. A 4 gloves isolator ISOFLEX-S is equiped with a Steritest pump and a H2O2 generator. The main advantage of using isolation technology for sterility testing is to assure that non-false positive results are obtained.

Both laboratories, KYMOS and PHARMAPROGRESS are GMP certified and we have a partial manufacturer authorization for Quality Control purposes. We offer the following services:

  • APIs Certificate of Analysis according to the relevant Pharmacopoeias
  • Individual parameter determination to be included in your batch Certificate of Analysis
  • Full analysis of all parameters to issue a stand alone batch Certificate of Analysis
  • Batch Testing and Batch Release of clinical batches
  • Batch Testing and Batch Release of marketing batches
  • Importation into the EU of medicinal drug products (human, veterinary or investigational)

We provide services of Elemental Impurities Analysis by ICP-MS according to ICH Q3D and European Pharmacopoeia and USP General Chapters <232>, <233> and <2232> for drug substances, excipients and drug products, including the 24 elements related in the ICH Q3D guideline and/or others.

We may suport you in the development of potency assay of vaccines for quality control in order to substitute "in vivo" testing. We are able to perform the development and validation of a new method from scratch or improving previous existing methods or commercial kits. We can transfer these methods to your lab or keep it in house to provide you routine quality control of batches under GMP.

Revised monographs in the European Pharmacopoeia on heparin sodium (0333) and heparin calcium (0332) are in force from January 1st, 2015. These monographs include chromogenic assays of anti-factor IIa and anti-factor Xa activities. USP monograph for Heparin sodium had been previously updated.

We have implemented and validated these challenging assays according to USP monograph and are ready to be used for drug product and drug substance. However, personalized method adjustments are necessary in a case by case basis.

Cleaning validation is a relevant GMP activity to prevent contamination of biopharmaceutical products by ensuring that the processing equipment is suitable for following manufacturing processes. Potential contaminants include residues of the active pharmaceutical ingredients or their related substances, and residues from the products used during the cleaning process such as solvents or detergents. This is particullary important for highly-sensitizing compounds such as antibiotics, hormones and cytotoxics and in the case of parenteral drug products.


Chemistry, Manufacturing & Control analytical services are conducted under GMP compliance. During development phases may be executed under GLP if it is a Client's requirement.



In biological substances coming from preclinical and clinical studies, we have a long track record in development and validation of bioanalytical methods from scratch or working with transferred methods. In addition we have a high capacity of sample processing. For the determination of plasma or serum levels of biologics for PK calculations, we mostly work with immunology methods such as ELISA, ECLA or RIA, but we also have experience in mass spectrometry of large molecules.

We develop new bioanalytical methods for immunogenicity studies of proteins and peptides following EMA and FDA guidelines on Immunogenicity of Therapeutic Proteins. Depending on the purpose and the stage of the research project, different studies should be performed:

  • Determination of Binding Antibodies: screening, confirmatory and titration
  • Neutralizing Antibodies
  • Antibody Typology
  • Cellular Immune Response

Our expertise in cell biology enables us to implement, validate and perform cell-based assays (CBA) for several applications like potency assays or neutralizing antibodies. We work with cells from primary cell lines, established cell lines obtained from cell banks of the clients and cultured at Kymos or with different kind of cells, for example immortalized cells lines or commercial arrested cell lines.

We offer services of pharmacokinetics calculations and statistics of bioanalytical data coming from preclinical and clinical studies.

  • Non-Compartmental Analysis (NCA)
  • Compartmental modeling using built-in models or self-generated ones
  • Bioequivalence (AUC, Tmax, Cmax)

We use the Phoenix WinNonlin® software that has been properly validated according to guidelines for IT system validation.

We offer you our experience in studies of Percutaneous Absorption for topical semisolid drug products using vertical diffusion cells (o Franz cells) according to Chapter <725> of the Pharmacopeial Forum. Both In Vitro Release Test and In Vitro Permeation Test are offered: